Almanac of Clinical MedicineAlmanac of Clinical Medicine2072-05052587-9294Moscow Regional Research and Clinical Institute (MONIKI)64010.18786/2072-0505-2017-45-7-547-552Assessment of the functional activity of platelets in chronic kidney disease stage 5DZeleninK. N.<p>MD, Head of Hemodialysis Unit</p><p>1 Suvorova ul., Arkhangelsk, 163001</p>fake@neicon.ruEsayanA. M.<p>MD, PhD, Professor, Chief of the Chair of Nephrology and Dialysis</p><p>6–8 L'va Tolstogo ul., Saint Petersburg, 197022</p>fake@neicon.ruRumyantsevA. Sh.<p>MD, PhD, Professor, Chair of Propedeutics of Internal Diseases, Chair of Faculty Therapy</p><p>8a 21-ya liniya Vasil'evskogo ostrova, Saint Petersburg, 199106</p><p>Tel.: +7 (812) 326 03 26</p><p>6–8 L'va Tolstogo ul., 197022</p><p>7–9 Universitetskaya naberezhnaya, Saint Petersburg, 199034</p>rash.56@mail.ruFirst City Clinical Hospital named after E.E. VolosevichPavlov First Saint Petersburg State Medical UniversitySaint Petersburg University151120174575475521101201811012018Copyright © 2017, Zelenin K.N., Esayan A.M., Rumyantsev A.S.2017<p><strong>Rationale:</strong> Thromboembolic complications in patients on hemodialysis have a significant impact on the duration and quality of life. <strong>Aim:</strong> To study the functional status of platelets in chronic kidney disease stage 5D (CKD-5D). <strong>Materials and methods:</strong> We examined 61 patients with CKD-5D. The duration of renal replacement therapy was 133 (74 to 177) months. The functional activity of platelets was evaluated in the adenosine diphosphate and adrenaline tests. <strong>Results:</strong> The functional activity of platelets in the adenosine diphosphate test was reduced in 35 (57.4%) of patients and unchanged in 26 (42.6%) patients. The functional activity of platelets in the adrenaline test was reduced in 38 (62.3%), normal in 8 (13.1%) and increased in 15 (24.6%) patients. <strong>Conclusion:</strong> In our study, only the adrenaline test was able to identify hyperactivity of platelets. We believe therefore, that the test with adrenaline is preferred for the study of the functional activity of platelets in CKD-5D. </p>chronic kidney diseasehemodialysisfunctional activity of plateletsхроническая болезнь почекгемодиализфункциональная активность тромбоцитов[1. Thomas M, Nesbitt C, Ghouri M, Hansrani M. Maintenance of hemodialysis vascular access and prevention of access dysfunction: a review. Ann Vasc Surg. 2017;43:318–27. doi: 10.1016/j.avsg.2017.02.014.][2. Sorrentino S, Studt JD, Medalia O, Tanuj Sapra K. Roll, adhere, spread and contract: structural mechanics of platelet function. Eur J Cell Biol. 2015;94(3–4):129–38. doi: 10.1016/j. ejcb.2015.01.001.][3. Строков АГ, Поз ЯЛ. Антикоагуляция при заместительной почечной терапии: классические подходы и новые возможности. Вестник трансплантологии и искусственных органов. 2010;12(4):80–5. doi: http://dx.doi. org/10.15825/1995-1191-2010-4-80-85.][4. Bauer A, Limperger V, Nowak-Göttl U. Endstage renal disease and thrombophilia. Hamostaseologie. 2016;36(2):103–7. doi: 10.5482/ HAMO-14-11-0063.][5. Михеева ЮС, Румянцев АШ, Есаян АМ. Нарушения в системе гемостаза и проблема тромбозов на хроническом гемодиализе. Нефрология. 2003;7(2):21–5.][6. Михеева ЮС, Румянцев АШ, Есаян АМ. Изменения гемостаза при хронической почечной недостаточности на стадии программного гемодиализа. Нефрология. 2003;7(1):72–5.][7.Oshima S, Noda K, Fukushima H, Nakamura S, Shono M, Kugimiya F, Higa K. Low respon siveness to thienopyridine in hemodialysis patients. Cardiovasc Interv Ther. 2010;25(1): 18–23. doi: 10.1007/s12928-009-0002-7.][8. Kim JS, Woo JS, Kim JB, Kim WS, Lee TW, Kim KS, Ihm CG, Kim W, Jeong KH. The pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis. Int J Cardiol. 2017;238:110–6. doi: 10.1016/j.ijcard.2017.03.026.][9. Martinović Z, Basić-Jukić N, Pavlović DB, Kes P. Importance of platelet aggregation in patients with end-stage renal disease. Acta Clin Croat. 2013;52(4):472–7.][10. Zeck J, Schallheim J, Lew SQ, DePalma L. Whole blood platelet aggregation and release reaction testing in uremic patients. Biomed Res Int. 2013;2013:486290. doi: 10.1155/2013/486290.]